tiprankstipranks
Arena Pharmaceuticals (ARNA)
NASDAQ:ARNA
US Market

Arena Pharma Stock Price & Analysis

0 Followers

ARNA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$45.50 - $100.00
Previous Close$0
VolumeN/A
Average Volume (3M)1.43M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
P/E Ratio-9.9
Beta0.55
Next EarningsN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-10.13
Shares Outstanding61,659,385
R-Squared0.03
Standard Deviation0.15
10 Day Avg. Volume905,389
30 Day Avg. Volume1,097,747
P/B Ratio8.60
P/S Ratio106899.11
P/CF Ratio4.50
P/FCF Ratio-11.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside― Upside
Rating ConsensusHold
Alpha0.03
Number of Analyst Covering11


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ARNA FAQ

What was Arena Pharma’s price range in the past 12 months?
Arena Pharma lowest stock price was $45.50 and its highest was $100.00 in the past 12 months.
    What is Arena Pharma’s market cap?
    Currently, no data Available
    When is Arena Pharma’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were Arena Pharma’s earnings last quarter?
    Currently, no data Available
    Is Arena Pharma overvalued?
    According to Wall Street analysts Arena Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
      Does Arena Pharma pay dividends?
      Arena Pharma does not currently pay dividends.
      What is Arena Pharma’s EPS estimate?
      Arena Pharma’s EPS estimate is -$10.13.
        How many shares outstanding does Arena Pharma have?
        Arena Pharma has 61,660,000 shares outstanding.
          What happened to Arena Pharma’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Arena Pharma?
          Among the largest hedge funds holding Arena Pharma’s share is Perceptive Advisors LLC. It holds Arena Pharma’s shares valued at 46M.

            ---

            Arena Pharma Stock Analysis

            Smart ScoreNeutral
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10
            4
            The Arena Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
            Learn more about TipRanks Smart Score

            Company Description

            Arena Pharmaceuticals

            Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.

            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            Eisai Co
            Evofem Biosciences
            Eiger Biopharmaceuticals
            Reata Pharmaceuticals
            Athersys

            Popular Stocks

            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis